|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, an orthotopic prostate cancer model was established to evaluate the <i>in vivo</i> effects of the combined targeting of CSCs and their interaction with TAMs on ADT resistance.<b>Results:</b> Autophagy-related gene 7 (ATG7) facilitated the transcription of OCT4 via β-catenin, which binds to the OCT4 promoter, promoting CSC characteristics in prostate cancer, including self-renewal, tumor initiation, and drug resistance.
|
29691294 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alpha-methylacyl-CoA racemase (AMACR) is highly overexpressed in prostate cancer (PCa) and its transcriptional regulators include various transcription factors and CTNNB1/β-catenin.
|
28741117 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of <i>PrKD1</i>.
|
29108267 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A marked difference was observed in the expression and distribution of β‑catenin in different prostate cancer cell lines.
|
28035382 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that the expression of beta-catenin and caveolin-1 may be prostate cancer- and race-specific.
|
28697756 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
APC or CTNNB1 mutations in colorectal, endometrial and prostate cancers activate the WNT/β-catenin signaling cascade.
|
28731148 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, our study demonstrates a novel role of the Akt1-β-catenin-TGFβ1 pathway in advanced PCa.
|
28602980 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the role of transcription factor 7 (TCF7), a transcription factor best known as a Wnt effector that forms a complex with β-catenin, in the development of advanced prostate cancer.
|
28220803 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Preclinical studies have demonstrated the potential of inhibitors that target WNT receptor complexes at the cell membrane or that block the interaction of β-catenin with lymphoid enhancer-binding factor 1 and the androgen receptor, in preventing prostate cancer progression.
|
28895566 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERT<sup>high</sup> Prostate Cancer Stem Cells.
|
28209613 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The levels of β-catenin and cyclin D1 in clinical PCa specimens were positively associated with Pin1 expression.
|
26497355 |
2016 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because mutations in adenomatous polyposis coli, β-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated.
|
25893287 |
2016 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that targeting Wnt/β-catenin or Akt pathways may increase the efficacy of taxane chemotherapy in advanced human prostate cancers that have lost PKCδ expression.
|
27196755 |
2016 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, to the best of our knowledge, the molecular association between FRAT1 and the β‑catenin/TCF pathway in prostate cancer has not been investigated.
|
27599661 |
2016 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
|
25909225 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As a translational research tool, OCP identified adaptive CTNNB1 amplifications/mutations in treated prostate cancers.
|
25925381 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the cellular origin of CaP in patients cannot be easily determined at present, the results imply that β-catenin inhibition is a potential therapeutic option for a subset of patients with basal-derived CaP.
|
25712462 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.
|
26509262 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, introducing δ-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating β-catenin and HIF-1α signaling under glucose shortage to amplify its tumor-promoting potential.
|
24727894 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
These studies indicate the involvement of AMPK in TRAIL-TZD-mediated apoptosis and β-catenin cleavage and suggest the possibility of utilizing AMPK as a therapeutic target in apoptosis-resistant prostate cancer.
|
26198640 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, a total of 61 patients with PCa and 10 patients with benign prostatic hyperplasia were included, and we showed that the expression of SFRP1 and β-catenin was correlated with the Gleason score, survival rate and response for endocrine therapy of PCa.
|
25719802 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer.
|
25130271 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that rottlerin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity with IC(50) values between 0.7 and 1.7 μM for prostate cancer PC-3 and DU145 cells and breast cancer MDA-MB-231 and T-47D cells.
|
24607787 |
2014 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer.
|
24823909 |
2014 |
|
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.
|
23752183 |
2014 |